Pyxis Oncology Files 8-K

TL;DR

Pyxis Oncology filed an 8-K on 12/19/24. Details TBD.

AI Summary

Pyxis Oncology, Inc. filed an 8-K on December 19, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Why It Matters

This filing indicates Pyxis Oncology is making a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural document without immediate financial or operational disclosures that would indicate high risk.

Key Players & Entities

• Pyxis Oncology, Inc. (company) — Registrant
• December 19, 2024 (date) — Date of Report
• 001-40881 (company) — Commission File Number
• 321 Harrison Avenue, Boston, Massachusetts 02118 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share PYXS The Nasdaq Global Se

Filing Documents

• pyxs-20241219.htm (8-K) — 45KB
• pyxs-ex99_1.htm (EX-99.1) — 28KB
• img244827169_0.jpg (GRAPHIC) — 46KB
• 0000950170-24-138563.txt ( ) — 255KB
• pyxs-20241219.xsd (EX-101.SCH) — 25KB
• pyxs-20241219_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On December 19, 2024, Pyxis Oncology, Inc. (the "Company") announced a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201, a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Forward Looking Statements

Forward Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation and press release, including without limitation statements regarding the Company's plans to develop, manufacture and commercialize its product candidates, including PYX-201; initial results, timing and progress of the Company's ongoing clinical trials; the expected results of the Company's clinical trials including those of PYX-201 and PYX-106; the expected benefits of the pipeline prioritization; the ability of initial and topline clinical data to de-risk PYX-201 and be confirmed with clinical trial progression, including the safety, tolerability, and potential efficacy of PYX-201 and PYX-106; the potential differentiation, advantage or effectiveness of PYX-201 compared to other approved products or products in development; the dosage and treatment potential of PYX-201; the size and future of the market; the plans and objectives of management, and the future results of operations and financial position of the Company, are forward-looking statements. These statements are neither promises nor guarantees, but are statements that involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in drug research and development, the Company's projected cash runway and potential needs for additional funding; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory appro

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 19, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Pyxis Oncology, Inc. Date: December 19, 2024 By: /s/ Pamela Connealy Pamela Connealy Chief Financial Officer and Chief Operating Officer